Animal models of neonatal stroke and response to erythropoietin and cardiotrophin-1.
Neonatal stroke is increasingly recognized in preterm and term infants, and the rate of arterial ischemic infarction occurring around the time of birth is as high as the annual incidence of large-vessel ischemic stroke in adults. Thus, neonatal stroke is a major contributor to perinatal morbidity and mortality, and a considerable number of these children will develop long-term neurodevelopmental disabilities. Our ability to investigate this situation has been limited by the technical challenges in developing suitable animal models. Our objective is to describe recent evidence in relation to animal models of neonatal stroke. In addition, we review and report potential neuroprotective strategies specific to neonatal stroke, with a focus on erythropoietin and cardiotrophin-1 because of their potential role in protection as well as repair.
Sola
Augusto
A
Division of Neonatology, MANA and Atlantic Neonatal Research Institute, Morristown, NJ 07960, USA. augustosolaneo@gmail.com
Peng
Hui
H
Rogido
Marta
M
Wen
Tong-Chun
TC
D000818:Animals; D000831:Animals, Newborn; D016207:Cytokines / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D009419:Nerve Tissue Proteins / Q000378:metabolism; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D013997:Time Factors
D016207:Cytokines; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D004921:Erythropoietin; C092073:cardiotrophin 1